arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Nkarta, Inc.

NKTX Health Care Biotechnology: Pharmaceutical Preparations
$2.92
Today
as of Sep 4, 16:52 ET
Last 30 days +29.20% Jul 27 → Sep 04
$2.02 $2.26 $2.50 $2.75 $2.99 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$2.77
High
$2.93
Low
$2.75
Volume
$446,755
Avg Vol
$772,262
Mkt Cap
$177M
P/E (TTM)
—
Beta
—
52w High
$3.72
52w Low
$1.70
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 1 item

Aug 10 · 20:24 PR GlobeNewswire
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

Overview

52-week range
$1.70
$3.72
60% of range
Avg surprise (last 3)
+7.9%
Avg reaction (last 2)
-0.2%
50% positive
Latest IV / EM
197%
EM ±30.8% · $3 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.68$-0.58$-0.48$-0.39$-0.29 Actual $-0.63Actual $-0.68Actual $-0.52Actual $-0.58Actual $-0.34Actual $-0.39Actual $-0.43Est $-0.44Actual $-0.31Est $-0.37Actual $-0.29Actual $-0.37Est $-0.39Actual $-0.54 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-40M$-36M$-32M$-27M$-23M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.54 — — — — financials
Tue May 12, 2026Mar/2026 $-0.37 $-0.39 +5.1% +13.9% +3.1% earnings
Tue Sep 30, 2025Sep 2025 $-0.29 — — — — financials
Tue Aug 12, 2025Jun/2025 $-0.31 $-0.37 +16.2% — — earnings
Wed May 14, 2025Mar/2025 $-0.43 $-0.44 +2.3% — -3.6% earnings
Mon Sep 30, 2024Sep 2024 $-0.39 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.34 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.58 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.52 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.68 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.63 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-43M$-31M—$-27M$-27M$-37M—$-34M
Net income$-40M$-28M—$-22M$-23M$-32M—$-28M
EPS (diluted)$-0.54$-0.37—$-0.29$-0.31$-0.43—$-0.39

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$25M$27M$40M$60M$53M$53M$28M$57M
Inventory————————
Total current assets$188M$236M$283M$289M$297M$272M$273M$290M
Total assets$338M$372M$404M$427M$448M$471M$501M$532M
Long-term debt————————
Total liabilities$90M$86M$92M$89M$91M$92M$93M$101M
Total equity$248M$286M$312M$338M$358M$379M$408M$431M

Implied volatility — last 90 days

47%304%561%818%1075% Jun 12 — IV 273% · EM ±28.0%Jun 19 — IV 182% · EM ±40.2%Jun 22 — IV 163% · EM ±34.0%Jun 23 — IV 226% · EM ±46.2%Jun 24 — IV 199% · EM ±39.8%Jun 25 — IV 180% · EM ±35.3%Jun 26 — IV 157% · EM ±30.0%Jun 29 — IV 170% · EM ±30.1%Jun 30 — IV 205% · EM ±35.3%Jul 01 — IV 168% · EM ±28.1%Jul 02 — IV 298% · EM ±48.1%Jul 03 — IV 308% · EM ±48.1%Jul 06 — IV 394% · EM ±54.5%Jul 07 — IV 470% · EM ±62.1%Jul 08 — IV 368% · EM ±46.1%Jul 09 — IV 501% · EM ±59.2%Jul 10 — IV 411% · EM ±45.5%Jul 13 — IV 365% · EM ±30.5%Jul 20 — IV 99% · EM ±23.3%Jul 21 — IV 117% · EM ±27.1%Jul 22 — IV 141% · EM ±32.2%Jul 23 — IV 184% · EM ±41.3%Jul 24 — IV 174% · EM ±38.5%Jul 27 — IV 117% · EM ±24.3%Jul 28 — IV 154% · EM ±31.5%Jul 29 — IV 199% · EM ±39.9%Jul 30 — IV 214% · EM ±41.9%Jul 31 — IV 250% · EM ±47.8%Aug 03 — IV 249% · EM ±44.2%Aug 04 — IV 167% · EM ±28.8%Aug 05 — IV 177% · EM ±29.5%Aug 06 — IV 148% · EM ±24.0%Aug 07 — IV 159% · EM ±24.9%Aug 10 — IV 168% · EM ±23.3%Aug 11 — IV 179% · EM ±23.6%Aug 12 — IV 184% · EM ±23.0%Aug 13 — IV 184% · EM ±21.7%Aug 14 — IV 214% · EM ±23.6%Aug 17 — IV 301% · EM ±25.1%Aug 18 — IV 315% · EM ±22.8%Aug 19 — IV 483% · EM ±28.5%Aug 20 — IV 1076% · EM ±44.9%Aug 24 — IV 92% · EM ±19.3%Aug 25 — IV 117% · EM ±24.0%Aug 26 — IV 47% · EM ±9.5%Aug 27 — IV 56% · EM ±10.9%Aug 28 — IV 118% · EM ±22.6%Aug 31 — IV 62% · EM ±11.1%Sep 01 — IV 140% · EM ±24.1%Sep 02 — IV 227% · EM ±38.0%Sep 03 — IV 222% · EM ±35.8%Sep 04 — IV 197% · EM ±30.8%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in